Biomarkers of peanut allergy in children over time
Background: Various biomarkers are used to define peanut allergy (PA). We aimed to observe changes in PA resolution and persistence over time comparing biomarkers in PA and peanut sensitised but tolerant (PS) children in a population-based cohort. Methods: Participants were recruited from the EAT and EAT-On studies, conducted across England and Wales, and were exclusively […]
INC Unveils Gen Z Preferences for Nuts and Dried Fruits and Snacking in Latin America
Peanuts, almonds and walnuts are consumed the most among Gen Z in Latin America 96% snack between meals, yogurt, dairy products, and fresh fruits being common choices Taste and health benefits are the primary drivers for consuming nuts and dried fruits INC’s NutTunes campaign set to encourage nut and dried fruit consumption through Spotify The […]
Peanut oral immunotherapy using an extensively heated and baked novel composition of peanuts
Background: Oral immunotherapy (OIT) is an increasingly acceptable therapeutic option for peanut-allergic (PA) children, despite significant side effects. Major peanut allergenic proteins are heat-resistant and are not rendered hypoallergenic after baking or cooking. Lyophilized peanut protein-MH (LPP-MH) is a novel composition from developing peanuts, enabling cooking-induced reduction in allergenicity. We aimed to explore the safety […]
BAT and MAT for diagnosis of peanut allergy: A systematic review and meta-analysis
Basophil activation test (BAT) or the mast cell activation test (MAT) are two in vitro tests that are currently being studied in food allergy as diagnostic tools as an alternative to oral food challenges (OFCs). We conducted a meta-analysis on BAT and MAT, assessing their specificity and sensitivity in diagnosing peanut allergy. Six databases were […]
Saliva antibody profiles are associated with reaction threshold and severity of peanut allergic reactions
Background: Reaction threshold and severity in food allergy are difficult to predict, and there is a lack of non-invasive predictors. Objectives: We sought to determine the relationships between pre-challenge levels of peanut (PN)-specific antibodies in saliva and reaction threshold, severity, and organ-specific symptoms during peanut allergic reactions. Methods: We measured PN-specific antibody levels in saliva […]
Follow-up to Adolescence after Early Peanut Introduction for Allergy Prevention
Background: A randomized trial demonstrated consumption of peanut from infancy to age 5 years prevented the development of peanut allergy. An extension of that trial demonstrated the effect persisted after 1 year of peanut avoidance. This follow-up trial examined the durability of peanut tolerance at age 144 months after years of ad libitum peanut consumption. […]
Prediction of pediatric peanut oral food challenge outcomes using machine learning
Background: Clinical testing, including food-specific skin and serum IgE level tests, provides limited accuracy to predict food allergy. Confirmatory oral food challenges (OFCs) are often required, but the associated risks, cost, and logistic difficulties comprise a barrier to proper diagnosis. Objective: We sought to utilize advanced machine learning methodologies to integrate clinical variables associated with […]
Design of the Intervention to Reduce Early Peanut Allergy in Children (iREACH): A practice-based clinical trial
Background: Introducing peanut products early can prevent peanut allergy (PA). The “Addendum guidelines for the prevention of PA in the United States” (PPA guidelines) recommend early introduction of peanut products to low and moderate risk infants and evaluation prior to starting peanut products for infants at high risk for PA (those with severe eczema and/or […]
Long-term Safety Results of Epicutaneous Immunotherapy (EPIT) with Viaskin Peanut in Peanut-Allergic Children Aged 4-11 Years in the Phase 3 PEOPLE Study
Rationale: Previously reported interim results from PEOPLE (PEPITES Open-Label Extension) demonstrated Viaskin Peanut 250 μg (VP250) led to continued treatment response and was well-tolerated out to 3 years. Here we report PEOPLE end-of-study safety results. Methods: In PEPITES, 356 peanut-allergic participants (aged 4-11 years) were randomized to placebo or VP250. In PEOPLE, 298 participants were […]
An Unintentional Randomized Trial of Early Environmental Exposure to Peanut: The Younger Siblings of LEAP Participants
Rationale: The Dual Allergen Exposure Hypothesis proposes that food allergy develops due to cutaneous exposure in the absence of oral consumption. Evaluation of the younger siblings of the Learning Early About Peanut (LEAP) participants provides an opportunity to understand the impact of environmental exposure to peanut during infancy and early childhood on the development of […]